IMG_5187.JPG
IHPtherapeutics_edited.png

Applying Glycobiology To Develop Novel Medicines

 

About

IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP compounds are novel small molecule glycan therapeutics that inhibit selectin and complement activity. IHP’s lead compound, IHP-102, is a dual P-selectin and complement inhibitor, which targets diseases in hematology and oncology. IHP-102 has potential as a prodromal rescue therapeutic for sickle cell disease patients in vaso-occlusive crisis. This would address a critical treatment gap and empower patients in home or outpatient settings. In addition, IHP-102 is also using a targeted, biomarker driven approach to treat solid tumors, based on established role of P-selectin & complement in certain cancers. Beyond, IHP-102, IHP is utilizing its considerable expertise in glycobiology to create novel, second generation glycans.

Mission

To pioneer the development of novel glyco-medicines

 

Our Team

psd.jpg

Rinko Ghosh, MS, MBA
President and CEO

IMG_4566.jpeg

Gabriel Njikang, PhD
Director of CMC

Jocelyn_Jackson_Q4736_HI_RES.jpg

Jocelyn Jackson
CFO

John_Paderi_Q5979_HI_RES.jpg

John Paderi, PhD

Chief Science Officer

Nate Bachtell Image.jpg
Web picture Jun16.jpeg

Peggy McLaughlin

VP of Clinical Operations

Kate2_Full Size.jpg

Kate Stuart, PhD

 VP of Program Management

j.jpg

Robert Van Gorp

VP of Strategic Sourcing

Board of Directors

psd.jpg

Rinko Ghosh, MS, MBA

Vlad.jpg

Vlad Hogenhuis, MD, MBA

John_Paderi_Q5979_HI_RES.jpg

John Paderi, PhD

Clinical and Scientific Advisors

Our Team

Nate IHP Image 2.png

Nathan Bachtell, MD
CMO

IMG_4566.jpeg

Gabriel Njikang, PhD
Director of CMC

psd.jpg

Rinko Ghosh, MS, MBA
President and CEO

John_Paderi_Q5979_HI_RES.jpg

John Paderi, PhD

Chief Science Officer

Jocelyn_Jackson_Q4736_HI_RES.jpg

Jocelyn Jackson
CFO

Kate2_Full Size.jpg

Kate Stuart, PhD

 VP of Program Management

Web picture Jun16.jpeg

Peggy McLaughlin

VP of Clinical Operations

j.jpg

Robert Van Gorp

VP of Strategic Sourcing

Board of Directors

psd.jpg

Rinko Ghosh, MS, MBA

Vlad.jpg

Vlad Hogenhuis, MD, MBA

John_Paderi_Q5979_HI_RES.jpg

John Paderi, PhD

Clinical and Scientific Advisors

 
Science Student

Science 

IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat a broad spectrum of diseases, including those involving immune regulation and inflammatory processes.

 

Pipeline

220428 - pipeline.png